| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 2 securities · may seek to influence control | ||||||
|
BiomX Inc.
13D/A
PHGE · 09090D103
|
1.0% |
6/23/2025
Event 6/18/2025
|
||||
| Orbimed Israel GP Ltd. | 1.0% | |||||
| Orbimed Israel Biofund GP Limited Partnership | 1.0% | |||||
| Gordon Carl L | 1.0% | |||||
| Chimovits Erez | 1.0% | |||||
|
Chemomab Therapeutics Ltd.
13D/A
CMMB · 16385C104
|
4.8% |
6/23/2025
Event 6/18/2025
|
||||
| Orbimed Israel Biofund GP Limited Partnership | 4.8% | |||||
| Orbimed Israel GP Ltd. | 4.8% | |||||
| Chimovits Erez | 4.8% | |||||
| Gordon Carl L | 4.8% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.